Granted Patent B2

US 11,701,424 · App. 16/904,511 · Granted Jul 18, 2023

Inventors: Mark White (Antioch, CA); Sandeep Kumar (San Bruno, CA); Christopher Chan (South San Francisco, CA); Spencer Liang (San Mateo, CA); Lance Stapleton (Oakland, CA); Andrew W. Drake (Mountain View, CA); Yosi Gozlan (Tel Aviv, IL); Ilan Vaknin (Tel Aviv, IL); Shirley Sameah-Greenwald (Kfar Saba, IL); Liat Dassa (Tel Aviv, IL); Zohar Tiran (Oranit, IL); Gad S. Cojocaru (Tel Aviv, IL); Maya Kotturi (Belmont, CA); Hsin-Yuan Cheng (San Mateo, CA); Kyle Hansen (San Francisco, CA); David Nisim Giladi (Netaniya, IL); Einav Safyon (Raanana, IL); Eran Ophir (Even Yehuda, IL); Leonard Presta (San Francisco, CA); Richard Theolis (Santa Cruz, CA); Radhika Desai (Brisbane, CA); Patrick Wall (Mill Valley, CA)

Assignee: COMPUGEN LTD.

A61K39/39558A61K39/39541A61P35/00C07K16/2803C07K16/2809C07K16/2818C07K16/2827A61K2039/505A61K2039/507A61K2039/572C07K2317/21C07K2317/24C07K2317/33C07K2317/34C07K2317/522C07K2317/524C07K2317/526C07K2317/53C07K2317/55C07K2317/56C07K2317/565C07K2317/622C07K2317/732C07K2317/76C07K2317/92C07K2317/94C07K2319/035C07K2319/33Y02A50/30

Abstract

Claims (38)

1. A method of activating T-cells of a patient with cancer comprising administering an anti-PD-L1 antibody and an anti-PVRIG antibody to said patient, wherein said anti-PVRIG antibody comprises:

i) a heavy chain comprising SEQ ID NO: 9, and

ii) a light chain comprising SEQ ID NO: 14.

2. The method according to claim 1 wherein said T-cells are cytotoxic T-cells (CTLs).

3. The method according to claim 1 wherein said T-cells are selected from the group consisting of CD4 + T-cells and CD8 + T-cells.

4. The method according to claim 1 wherein said activation is measured as an increase in interferon-γ production and/or an increase in cytokine secretion.

5. The method according to claim 1 , wherein the anti-PD-L1 antibody is selected from the group consisting of atezolizumab, avelumab, and durvalumab.

6. The method according to claim 5 , wherein the anti-PD-L1 antibody is atezolizumab.

7. The method according to claim 5 , wherein the anti-PD-L1 antibody is avelumab.

8. The method according to claim 5 , wherein the anti-PD-L1 antibody is durvalumab.

9. A method of activating T-cells of a patient with cancer comprising administering an anti-PD-L1 antibody and an anti-PVRIG antibody to said patient, wherein said anti-PVRIG antibody comprises:

i) a heavy chain comprising SEQ ID NO: 19, and

ii) a light chain comprising SEQ ID NO: 24.

10. The method according to claim 1 wherein said T-cells are cytotoxic T-cells (CTLs).

11. The method according to claim 1 wherein said T-cells are selected from the group consisting of CD4 + T-cells and CD8 + T-cells.

12. The method according to claim 1 wherein said activation is measured as an increase in interferon-γ production and/or an increase in cytokine secretion.

13. The method according to claim 1 , wherein the anti-PD-L1 antibody is selected from the group consisting of atezolizumab, avelumab, and durvalumab.

14. The method according to claim 13 , wherein the anti-PD-L1 antibody is atezolizumab.

15. The method according to claim 13 , wherein the anti-PD-L1 antibody is avelumab.

16. The method according to claim 13 , wherein the anti-PD-L1 antibody is durvalumab.

17. A method of activating T-cells of a patient with cancer comprising administering an anti-PD-1 antibody and an anti-PVRIG antibody to said patient, wherein said anti-PVRIG antibody comprises:

i) a heavy chain comprising SEQ ID NO: 9, and

ii) a light chain comprising SEQ ID NO: 14.

18. The method according to claim 17 wherein said T-cells are cytotoxic T-cells (CTLs).

19. The method according to claim 17 wherein said T-cells are selected from the group consisting of CD4 + T-cells and CD8 + T-cells.

20. The method according to claim 17 wherein said activation is measured as an increase in interferon-γ production and/or an increase in cytokine secretion.

21. The method according to claim 17 , wherein the anti-PD-1 antibody is selected from the group consisting of pembrolizumab and nivolumab.

22. The method according to claim 21 , wherein the anti-PD-1 antibody is pembrolizumab.

23. The method according to claim 21 , wherein the anti-PD-1 antibody is nivolumab.

24. A method of activating T-cells of a patient with cancer comprising administering an anti-PD-1 antibody and an anti-PVRIG antibody to said patient, wherein said anti-PVRIG antibody comprises:

i) a heavy chain comprising SEQ ID NO: 19, and

ii) a light chain comprising SEQ ID NO: 24.

25. The method according to claim 24 wherein said T-cells are cytotoxic T-cells (CTLs).

26. The method according to claim 24 wherein said T-cells are selected from the group consisting of CD4 + T-cells and CD8 + T-cells.

27. The method according to claim 24 wherein said activation is measured as an increase in interferon-γ production and/or an increase in cytokine secretion.

28. The method according to claim 24 , wherein the anti-PD-1 antibody is selected from the group consisting of pembrolizumab and nivolumab.

29. The method according to claim 28 , wherein the anti-PD-1 antibody is pembrolizumab.

30. The method according to claim 28 , wherein the anti-PD-1 antibody is nivolumab.

Assignments (3)

Continuity (10)

Cited By (1)

US 12,570,744